Pharmaceutical company Bristol-Myers Squibb (BMY) will raise its quarterly dividend by 2.8 percent to $0.37 per share. It's the seventh consecutive year of dividend increases for Bristol-Myers. The indicated dividend yield is 2.5%.

Bristol-Myers Squibb Company is is a global specialty biopharmaceutical company.  Bristol-Myers is developing new medicines in the following core therapeutic areas: oncology with a priority in certain tumor types; immunoscience with priorities in psoriasis, lupus, RA and inflammatory bowel disease;  cardiovascular with a priority in heart disease and; fibrotic disease with priorities in lung and liver. The company's top drugs include Opdivo (infused biologic immuno-oncology treatment) and Eliquis (anticoagulation).